psma-617 has been researched along with Pain* in 1 studies
1 trial(s) available for psma-617 and Pain
Article | Year |
---|---|
Health-related quality of life and pain outcomes with [
In VISION, the prostate-specific membrane antigen (PSMA)-targeted radioligand therapy lutetium-177 [. This multicentre, open-label, randomised, phase 3 trial was conducted at 84 cancer centres in nine countries in North America and Europe. Eligible patients were aged 18 years or older; had progressive PSMA-positive metastatic castration-resistant prostate cancer; an Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2; and had previously received of at least one androgen receptor pathway inhibitor and one or two taxane-containing regimens. Patients were randomly assigned (2:1) to receive either [. Between June 4, 2018, and Oct 23, 2019, 831 patients were enrolled, of whom 581 were randomly assigned to the [. [. Advanced Accelerator Applications (Novartis). Topics: Aged; Androgen Receptor Antagonists; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Pain; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Receptors, Androgen; Standard of Care; Taxoids | 2023 |